Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. The Series A financing is led by MPM Capital, with Fidelity Biosciences, ARCH Venture Partners, and Medtronic participating.
http://ift.tt/1FAt6fT
http://ift.tt/1FAt6fT
No comments:
Post a Comment